Cure8 research brief
Ustekinumab is already approved for moderate-to-severe Crohn's disease; this real-world study reports encouraging longer-term clinical, biological, and endoscopic outcomes up to 96 weeks and suggests good treatment persistence and tolerability in a largely bio-naïve Chinese cohort.
Adults with Crohn's disease (especially those considering or currently on biologics), clinicians managing biologic therapy, and researchers studying long-term biologic effectiveness.
This is a real-world retrospective study (single center) using available follow-up data at specific time points; outcomes are reported as percentages of patients with data at each time. The study suggests UST had durable effectiveness and an acceptable safety profile in this cohort, including bio-naïve and previously biologic-exposed patients.
Factors associated with higher chance of clinical remission at week 24 included absence of perianal lesions and normal serum albumin. Endoscopic reassessment was limited to a subset and showed endoscopic improvement in many but not all patients.
Limitations: The design is retrospective and single-center, follow-up and some outcomes (biologic, endoscopic remission) were available only in subsets, and the abstract does not provide full methodological detail or adjusted outcome measures. These points mean results may not generalize to all settings.
This is a retrospective, single-center cohort with outcomes reported for patients with available data at each time point. Endoscopic and biomarker data were available only for subsets of patients. The structured content depth is an abstract; Cure8 did not review the full paper beyond the provided abstract.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
For people with moderate–severe Crohn’s disease who failed anti‑TNF drugs, this trial suggests risankizumab may achieve higher corticosteroid‑free clinical and endoscopic remission than ustekinumab, which could mean...
This study analyzes thousands of adverse event reports for ustekinumab in Crohn’s disease and highlights infections plus possible cardiovascular and neuropsychiatric signals that clinicians and patients may want to...
People with Crohn’s disease on ustekinumab may be more likely to need intensified dosing if they previously tried biologics or immunomodulators or have had disease longer; this could affect monitoring and planning. For...
